Unloxcyt (cosibelimab-ipdl)

P3, N=25, Terminated, Checkpoint Therapeutics, Inc. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023

P1, N=500, Recruiting, Checkpoint Therapeutics, Inc. | Trial completion date: Dec 2023 --> Dec 2024

In recent years, the combination therapy of nivolumab plus ipilimumab has gained ground in studies for its survival and response rate benefits in patients with advanced melanoma...On the contrary, in advanced and metastatic BCC, successful therapeutic strategies, such as vismodegib and sonidegib, are based on the inhibition of aberrant activation of the Hedgehog signaling pathway...In patients with locally advanced or metastatic SCC, who are not candidates for surgery or radiotherapy, anti-PD1 agents such as cemiplimab, pembrolizumab, and cosibelimab (CK-301) have shown significant results in terms of response rate. PD-1/PD-L1 inhibitors, such as avelumab, have also been used in Merkel carcinoma, achieving responses in half of the patients with advanced disease...Two of the most promising molecules used in combination with immunotherapy are cavrotolimod (a Toll-like receptor 9 agonist) and a Toll-like receptor 7/8 agonist...Neoadjuvant treatment with cemiplimab in CSCCs and nivolumab in MCCs has shown promising results. Despite the successes of these new drugs, the new challenges ahead will be to select patients who will benefit from these treatments based on biomarkers and parameters of the tumor microenvironment.

P3, N=25, Terminated, Checkpoint Therapeutics, Inc. | N=560 --> 25 | Trial completion date: Dec 2025 --> Dec 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Dec 2022; Regional political conflict

P3, N=560, Active, not recruiting, Checkpoint Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: May 2024 --> Dec 2024

P3, N=560, Recruiting, Checkpoint Therapeutics, Inc. | Not yet recruiting --> Recruiting | Initiation date: Sep 2021 --> Dec 2021

P1, N=500, Recruiting, Checkpoint Therapeutics, Inc. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jul 2021 --> Nov 2021

P3, N=560, Not yet recruiting, Checkpoint Therapeutics, Inc. | Initiation date: Jun 2021 --> Sep 2021

P3, N=560, Not yet recruiting, Checkpoint Therapeutics, Inc.